D
Sell
8/30/2024Upgraded
Tourmaline Bio, Inc. (TRML) was upgraded to D- from E+ on 8/30/2024 due to an increase in the volatility index and total return index.
E
Sell
8/15/2024Downgrade
Tourmaline Bio, Inc. (TRML) was downgraded to E+ from D- on 8/15/2024 due to a decline in the growth index, solvency index and valuation index. EBIT declined 25.43% from -$17.52M to -$21.97M, the quick ratio declined from 60.71 to 45.52, and earnings per share declined from -$0.5527 to -$0.6798.
D
Sell
8/8/2024Upgraded
Tourmaline Bio, Inc. (TRML) was upgraded to D- from E+ on 8/8/2024 due to an increase in the total return index and volatility index.
E
Sell
7/19/2024Downgrade
Tourmaline Bio, Inc. (TRML) was downgraded to E+ from D- on 7/19/2024 due to a large decline in the volatility index, growth index and total return index. Operating cash flow declined 59.55% from -$9.35M to -$14.92M, and EBIT declined 17.64% from -$14.89M to -$17.52M.
D
Sell
4/11/2024Downgrade
Tourmaline Bio, Inc. (TRML) was downgraded to D- from D on 4/11/2024 due to a decline in the volatility index and total return index.
D
Sell
3/21/2024Upgraded
Tourmaline Bio, Inc. (TRML) was upgraded to D from E on 3/21/2024 due to a significant increase in the solvency index, total return index and growth index. The quick ratio increased from 14.48 to 40.57, earnings per share increased from -$1.2994 to -$0.8062, and EBIT increased 9.06% from -$16.37M to -$14.89M.
E
Sell
1/17/2024None
Tourmaline Bio, Inc. (TRML) was downgraded to E from U on 01/17/2024.
